The Efficacy of Japanese Herbal Kampo Medicine as an Acute and Prophylactic Medication to Treat Chronic Daily Headache and Medication Overuse Headache:-Single Arm Retrospective Study

Katsuki, Masahito; Kashiwagi, Kenta; Kawamura, Shin; Koh, Akihito

doi:10.7759/cureus.25419

Cited by 15 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other details are described in Table 1. Five of the eight patients took Japanese herbal Kampo medicine [14,15] as prophylaxis before CGRP-mABs treatment.…”

Section: Resultsmentioning

confidence: 99%

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention

Katsuki¹,

Kashiwagi²,

Kawamura³

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

BackgroundThere are no reports on the effectiveness of one-time use of the calcitonin gene-related peptide-related monoclonal antibodies (CGRP-mABs) evaluated at one and three months for migraine prevention. Here, we present the real-world data of one-time administration of CGRP-mABs, galcanezumab and fremanezumab, for migraine prevention. MethodologyWe retrospectively investigated eight migraine patients treated with one-time administration of galcanezumab 240 mg or fremanezumab 225 mg. Monthly headache days (MHD), monthly acute medication intake days (AMD), and Headache Impact Test-6 (HIT-6) scores before, one, and three months after one-time CGRP-mABs administration were evaluated. ResultsA total of five women and three men were included (median age = 46.5 years, range = 19-63 years). Overall, six were episodic migraine, and two were chronic migraine. Five patients received one-time administration of fremanezumab and three received galcanezumab. In total, six (75.0%) patients experienced therapeutic effectiveness one month after the one-time administration. Five of the six maintained the therapeutic effect until three months, but one had aggravation. As a result, six (75.0%) patients reached or maintained therapeutic conditions three months after the one-time administration of CGRP-mABs without side effects. All patients continued previously used oral prophylaxis during the observational period. Significant reductions in MHD, AMD, and HIT-6 scores were observed three months after the initial administration (p = 0.008, p = 0.005, and p < 0.001, respectively). ConclusionsSix of the eight patients experienced or maintained therapeutic effectiveness at three months despite the one-time administration of CGRP-mABs. Our results suggest that one-time use of CGRP-mABs may be a new treatment option in combination with oral prophylaxis.

show abstract

“…Other details are described in Table 1. Five of the eight patients took Japanese herbal Kampo medicine [14,15] as prophylaxis before CGRP-mABs treatment.…”

Section: Resultsmentioning

confidence: 99%

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention

Katsuki¹,

Kashiwagi²,

Kawamura³

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, 10 (41.70%) did not use acute medication. Only one (4.17%) individual used prophylactic medication of Japanese herbal kampo goreisan [ 18 , 30 , 31 ] ( Figure 2 ). Ten (41.70%) had hypertension, two (8.3%) had dyslipidemia, and the other two had back or knee pains ( Figure 3 ).…”

Section: Resultsmentioning

confidence: 99%

“…This could be due to the fact that lifestyle-related diseases are now being properly treated so that more people are taking antihypertensive drugs that also function as migraine prophylactics, and people are becoming more educated over time [ 41 ]. Another possibility is that Japanese herbal kampo medicines are commonly prescribed for the elderly in Japan and used as an acute alternative therapy for headache disorders [ 18 , 30 , 42 ], preventing the abuse of common analgesics. In addition, the fact that the elderly have more TTH [ 6 , 7 ] and often tolerate it until it improves without the use of acute medications may reduce the rate of MOH development.…”

Section: Discussionmentioning

confidence: 99%

“…However, we only investigated the working-age population. Therefore, headache [ 14 , 15 ], migraine [ 15 , 16 , 17 ], chronic daily headache (CDH) [ 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 ], and MOH [ 12 , 14 , 15 , 17 , 19 , 21 ] prevalence among the elderly in recent years was not sufficiently investigated by a population-based survey in Japan. CDH in this context means as a case with headaches occurring at least 15 days per month for three or more consecutive months [ 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Questionnaire-Based Survey during COVID-19 Vaccination on the Prevalence of Elderly’s Migraine, Chronic Daily Headache, and Medication-Overuse Headache in One Japanese City—Itoigawa Hisui Study

Katsuki¹,

Kawahara²,

Matsumori³

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: The prevalence of headache disorders, migraine, chronic daily headache (CDH), and medication-overuse headache (MOH) among the elderly in Japan has not been sufficiently investigated. We performed a questionnaire-based survey and revealed 3-month headache prevalence and headaches’ characteristics. Methods: The population aged over 64 was investigated in Itoigawa during their third coronavirus disease 2019 vaccination. Migraine, MOH was defined as The International Classification of Headache Disorders Third edition. CDH was defined as a headache occurring at least 15 days per month. K-means++ were used to perform clustering. Results: Among 2858 valid responses, headache disorders, migraine, CDH, and MOH prevalence was 11.97%, 0.91%, 1.57%, and 0.70%, respectively. Combined-analgesic and non-opioid analgesic were widely used. Only one migraineur used prophylactic medication. We performed k-means++ to group the 332 MOH patients into four clusters. Cluster 1 seemed to have tension-type headache-like headache characteristics, cluster 2 seemed to have MOH-like headache characteristics, cluster 3 seemed to have severe headaches with comorbidities such as dyslipidemia, stroke, and depression, and cluster 4 seemed to have migraine-like headache characteristics with photophobia and phonophobia. Conclusions: This is the largest prevalence survey in the Japanese elderly. Headache disorders are still the elderly’s burden. Clustering suggested that severe headaches associated with some comorbidities may be unique to the elderly.

show abstract

“…Depending on the severity, we prescribed acute medications such as non-steroidal anti-inflammatory drugs, triptans, and lasmiditan, and novel 5-HT receptor agonists with high affinity and selectivity for the 5-HT 1F serotonin receptor. In addition, we also prescribed prophylactic medications, such as lomerizine, propranolol, valproic acid, amitriptyline, muscle relaxants, and Kampo medicine [16][17][18] (goreisan, goshuyuto, and yokukansan). The patients were referred to a nearby headache hospital if monoclonal calcitonin gene-related peptide antibodies were indicated as prophylactic medicine.…”

Section: General Managementmentioning

confidence: 99%

The First Case Series From Japan of Primary Headache Patients Treated by Completely Online Telemedicine

Katsuki¹

2022

Cureus

Self Cite

View full text Add to dashboard Cite

BackgroundSince March 2020, the coronavirus disease 2019 pandemic has increased the need for telemedicine to avoid in-person consultations. Online clinics for most diseases officially started in Japan in April 2022. Here, we report the cases of eight Japanese headache patients treated by completely online telemedicine for three months from the first visit. MethodologyFrom the medical records between July 2022 and October 2022, we retrospectively investigated eight consecutive first-visit primary headache patients who consulted our online headache clinic via telemedicine and continued to see us via telemedicine only. The Headache Impact Test-6 (HIT-6) score, monthly headache days (MHD), and monthly acute medication intake days (AMD) were investigated over the observation period. ResultsA total of eight women were included, and the median (interquartile range) age was 30 (24-51) years. The median HIT-6 scores before, one, and three months after treatment were 63 (58-64), 54 (53-62), and 52 (49-54), respectively. MHD before, one, and three months after treatment were 15 (9-28), 12 (3-17), and 2 (2-8), respectively. AMD before, one, and three months after treatment were 10 (3-13), 3 (1-8), and 2 (0-3), respectively. Significant reductions in HIT-6 and MDH were observed three months after the initial consultation (p = 0.007 and p = 0.042, respectively). AMD was not significantly decreased at three months (p = 0.447). ConclusionsThis is the first report of Japanese patients treated by completely online telemedicine for three months from the first visit. HIT-6 and MDH can be significantly decreased at three months by only telemedicine. Online telemedicine is expected to be widely used to resolve unmet needs in headache treatment.

show abstract

The Efficacy of Japanese Herbal Kampo Medicine as an Acute and Prophylactic Medication to Treat Chronic Daily Headache and Medication Overuse Headache:-Single Arm Retrospective Study

Cited by 15 publications

References 24 publications

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention

Questionnaire-Based Survey during COVID-19 Vaccination on the Prevalence of Elderly’s Migraine, Chronic Daily Headache, and Medication-Overuse Headache in One Japanese City—Itoigawa Hisui Study

The First Case Series From Japan of Primary Headache Patients Treated by Completely Online Telemedicine

Contact Info

Product

Resources

About